Search

Myriad Genetics Inc

Suletud

SektorTervishoid

3.11 -2.51

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3

Max

3.2

Põhinäitajad

By Trading Economics

Sissetulek

-9.1M

-43M

Müük

-9.7M

191M

Aktsiakasum

-0.33

Kasumimarginaal

-22.653

Töötajad

2,700

EBITDA

-8.5M

-26M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+32.13% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

2. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-223M

292M

Eelmine avamishind

5.62

Eelmine sulgemishind

3.11

Uudiste sentiment

By Acuity

13%

87%

17 / 340 Pingereas Healthcare

Myriad Genetics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. aug 2026, 20:02 UTC

Myriad Genetics Inc shares are lower amid broader market declines and geopolitical concerns. Earlier, the stock dropped significantly before stabilizing during trading.

21. aug 2026, 19:26 UTC

Myriad Genetics Inc. shares are lower today, trading below their 20-day moving average amid a broader market rebound in safe-haven assets.

20. aug 2026, 19:52 UTC

Myriad Genetics Inc shares are higher during Thursday's session, reaching a session high earlier. No specific company news was identified to explain the movement.

19. aug 2026, 20:02 UTC

Myriad Genetics shares are trading higher, rebounding from pre-market losses amid strong buying interest during the session. The stock remains near its one-month low.

18. aug 2026, 20:03 UTC

News

Myriad Genetics shares are trading lower amid an investigation and revised revenue guidance of $770-$790 million, down from $860-$880 million.

17. aug 2026, 19:26 UTC

Myriad Genetics Inc. shares are higher today, reaching a peak late in the session, though they remain below their 20-day moving average.

14. aug 2026, 19:46 UTC

News

Myriad Genetics Inc. shares are lower amid an investigation by Bronstein, Gewirtz & Grossman, LLC, and disappointing Q2 results with revised revenue guidance.

13. aug 2026, 19:41 UTC

News

Myriad Genetics shares are lower as the company faces an investigation and lowers its full-year revenue guidance to $770-$790 million.

12. aug 2026, 19:31 UTC

News

Myriad Genetics Inc shares are lower as the company faces an investigation and reports declining Q2 revenue of $190.7 million, missing expectations.

11. aug 2026, 20:06 UTC

News

Myriad Genetics Inc shares are lower amid a securities investigation and disappointing Q2 results, which included a revenue decline and lowered full-year guidance.

7. aug 2026, 19:51 UTC

Myriad Genetics shares are higher today, driven by a broader advance in biotechnology stocks. The move breaks from a recent pattern of higher daily closes.

6. aug 2026, 20:03 UTC

Shares of Myriad Genetics are trading higher today, despite fluctuations during the session. The overall trend remains positive since Wednesday's close.

5. aug 2026, 21:21 UTC

Myriad Genetics Inc shares are higher in after-market hours, reflecting broader market gains amid positive technology stock performance and favorable economic data.

4. aug 2026, 20:04 UTC

Myriad Genetics shares are higher today, supported by overall market gains and positive sentiment amid declining crude oil prices and comments on potential peace talks with Iran.

3. aug 2026, 20:03 UTC

News

Myriad Genetics gains amid broader market strength, tightening revenue guidance to $770 million to $790 million while facing reimbursement challenges. Shares remain higher since Friday.

31. juuli 2026, 23:11 UTC

Myriad Genetics Inc shares are higher in after-market hours, recovering from earlier lows. The stock remains below its 20-day moving average.

30. juuli 2026, 22:51 UTC

News

Myriad Genetics shares fell in after-market trading following disappointing Q2 results, with revenue of $190.7 million missing expectations and a revised revenue outlook.

29. juuli 2026, 18:07 UTC

Myriad Genetics Inc. shares are lower today, continuing a four-session decline amid broader market concerns over rising crude oil prices and inflation worries.

28. juuli 2026, 18:06 UTC

News

Myriad Genetics faces negative sentiment after being labeled unprofitable. Shares are lower today, continuing a trend of declines over the past three sessions.

27. juuli 2026, 18:16 UTC

Myriad Genetics shares are lower amid a broader market trend and significant declines in crude oil prices, despite earlier session volatility.

24. juuli 2026, 19:36 UTC

Event
News

Myriad Genetics shares are lower amid scrutiny over financial performance and stagnant revenue growth, reflecting ongoing challenges in the broader market.

22. juuli 2026, 20:06 UTC

Myriad Genetics Inc shares are lower today, continuing a decline from Tuesday's close amid mixed sentiment ahead of the Federal Reserve meeting.

20. juuli 2026, 18:22 UTC

Myriad Genetics Inc. shares are lower today, continuing a recent decline amid rising U.S. Treasury yields and inflation concerns tied to increasing oil prices.

Võrdlus sarnastega

Hinnamuutus

Myriad Genetics Inc Prognoos

Hinnasiht

By TipRanks

32.13% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD  32.13%

Kõrge 8.5 USD

Madal 2.5 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Myriad Genetics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

7 ratings

1

Osta

4

Hoia

2

Müü

Sentiment

By Acuity

17 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
help-icon Live chat